HBeAg阳性慢性HBV 感染分期和治疗新进展

doi:10.3969/j.issn.1672-5069.2023.05.003

Abstract

Peng Zhen, Ning Huibin, Li Kuan, et al. Infection staging and antiviral strategy in individuals with chronic serum HBeAg-positive hepatitis B viral infection[J]. Journal of Practical Hepatology, 2023, 26(5): 615-617.

References

[1] 中华医学会肝病学分会. 扩大慢性乙型肝炎抗病毒治疗的专家意见. 中华肝脏病杂志,2022,30(2):131-136.
[2] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2022年版).实用肝脏病杂志,2023,26(3)S18-39.
[3] Likhitsup A, Lok AS. Understanding the natural history of hepatitis B virus infection and the new definitions of cure and the endpoints of clinical trials. Clin Liver Dis, 2019,23(3):401-416.
[4] Yim HJ, Kim JH, Park JY, et al. Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop. Clin Mol Hepatol, 2020,26(4):411-429.
[5] Hui CK, Leung N, Yuen ST, et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology, 2007,46(2):395-401.
[6] EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol, 2017,67(2):370-398.
[7] Huang DQ, Li X, Le MH, et al. Natural history and hepatocellular carcinoma risk in untreated chronic hepatitis B patients with indeterminate phase. Clin Gastroenterol Hepatol, 2022,20(8):1803-1812,e5.
[8] Spradling PR, Xing J, Rupp LB, et al. Distribution of disease phase, treatment prescription and severe liver disease among 1598 patients with chronic hepatitis B in the Chronic Hepatitis Cohort Study, 2006-2013. Aliment Pharmacol Ther, 2016,44(10):1080-1089.
[9] 刘春云, 常丽仙, 李俊义,等. HBV感染免疫耐受期肝组织炎症和纤维化的影响因素分析. 临床肝胆病杂志,2022,38(9):2005-2009.
[10] 曾湛, 高媛娇, 毕潇月,等. HBsAg水平对ALT正常的HBeAg阳性慢性HBV感染者肝脏炎症发生的预测价值. 临床肝胆病杂志,2022,38(5):1030-1034.
[11] Lee WM. Hepatitis B virus infection. N Engl J Med, 1997,337(24):1733-1745.
[12] 辛杰晶, 东冰, 任丹丹,等. ALT正常HBeAg阳性慢性HBV感染者免疫耐受期与不确定期临床特征. 中华临床感染病杂志,2022,15(4):285-290.
[13] Lee HA, Kim SU, Seo YS, et al. Comparable outcomes between immune-tolerant and active phases in noncirrhotic chronic hepatitis B: a meta-analysis. Hepatol Commun, 2023,7(2):e0011.
[14] Lee HW, Chon YE, Kim BK, et al. Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B. Eur J Intern Med, 2021,84:68-73.
[15] Seong G, Sinn DH, Kang W, et al. Age and fibrosis index for the prediction of hepatocellular carcinoma risk in patients with high hepatitis B virus DNA but normal alanine aminotransferase. Eur J Gastroenterol Hepatol, 2022,34(1):69-75.
[16] Kim DY. History and future of hepatitis B virus control in South Korea. Clin Mol Hepatol, 2021,27(4):620-622.
[17] Lee HA, Lee HW, Kim IH, et al. Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase. Aliment Pharmacol Ther, 2020,52(1):196-204.
[18] Yoo JJ, Park SY, Moon JE, et al. Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase. Clin Mol Hepatol, 2023,29(2):482-495.
[19] Yapali S, Talaat N, Fontana RJ, et al. Outcomes of patients with chronic hepatitis B who do not meet criteria for antiviral treatment at presentation. Clin Gastroenterol Hepatol, 2015,13(1):193-201,e1.
[20] Ning Q, Han M, Sun Y, et al. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial). J Hepatol, 2014,61(4):777-784.
[21] Wang Q, Li H, Ding D, et al. Upgrade combination response is limited by prolonged nucelos(t)ide analogue therapy in HBeAg-positive chronic hepatitis B: A real-life study. J Clin Transl Hepatol, 2018,6(1):11-17.
[22] 专家意见编写组. 慢性乙型肝炎抗病毒治疗药物临床试验技术指导原则专家意见. 中华肝脏病杂志,2022,30(5):493-504.
[23] Fanning GC, Zoulim F, Hou J, et al. Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat Rev Drug Discov, 2019,18(11):827-844.

Infection staging and antiviral strategy in individuals with chronic serum HBeAg-positive hepatitis B viral infection

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Sheng Qiuju, Dou Xiaoguang. Therapeutic strategies and benefit evaluation in patients with chronic hepatitis B viral infection [J]. Journal of Practical Hepatology, 2023, 26(5): 609-611.
[2]	Zhang Dan, Ding Yang. Serum viral loads-oriented disease status and antiviral strategies in patients with chronic hepatitis B viral infection [J]. Journal of Practical Hepatology, 2023, 26(5): 612-614.
[3]	Huang Baisheng, Ou Lanxin, Zhang Yinjie, et al. Diagnostic performance of FibroScan and GPR, APRI and FIB-4 for liver fibrosis evaluation in patients with chronic hepatitis B virus infection without serum alanine aminotransferase elevation [J]. Journal of Practical Hepatology, 2023, 26(5): 618-621.
[4]	Wu Yulong, Zhuang Jianqi, Liu Zhicheng, et al. Changes of serum HBV pgRNA levels in patients with chronic hepatitis B receiving nucleos(t)ide analogues treatment [J]. Journal of Practical Hepatology, 2023, 26(5): 622-625.
[5]	Wang Yizhuo, Zhang Weiqi, Li Hong. A 3-year follow-up of patients with serum HBeAg-positive chronic hepatitis B after 48 to 72 week pegylated interferon α-2a treatment [J]. Journal of Practical Hepatology, 2023, 26(5): 626-629.
[6]	Hao Anhua, Du Zhongcai, Zhou Lin, et al. Changes of liver stiffness measurement and S index in patients with chronic hepatitis B and their performance in evaluating liver fibrosis [J]. Journal of Practical Hepatology, 2023, 26(5): 630-633.
[7]	Liu Aihua, Fu Jian, Chen Xiaohong. Predicting performance of liver stiffness measurement and GGT/PLT ratio combination in judging liver fibrosis in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2023, 26(5): 634-637.
[8]	Li Yaling, Yang Facheng, Jiang Yaxi. Virological response to direct acting antivirals in patients with chronic hepatitis C and liver fibrosis [J]. Journal of Practical Hepatology, 2023, 26(5): 638-641.
[9]	Cai Tao, Wei Wei, Wang Xinwen, et al. Direct acting antivirals in treatment of patients with chronic end-stage renal disease and concomitant hepatitis C virus infection [J]. Journal of Practical Hepatology, 2023, 26(5): 642-645.
[10]	Luo Liangde, Su Jianming, Ren Chengguo, et al. Oral glycyrrhizin and fenofibrate administration in treatment of patients with metabolic associated fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(5): 650-653.
[11]	Mo Junqiao, Lin Jing, Yang Li. Improvement of liver function tests by silibinin and polyene phosphatidylcholine combination therapy in patients with anti-tuberculosis drugs-induced liver injury [J]. Journal of Practical Hepatology, 2023, 26(5): 666-669.
[12]	Wu Xianghui, Li Longhu, Jing Feihua, et al. One-year survival of patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization and radiofrequency ablation combination therapy [J]. Journal of Practical Hepatology, 2023, 26(5): 702-705.
[13]	Chen Changguang, Xiao Rong, Wang Jun. Sequential drug-eluting beads-transcatheter arterial chemoembolization and radiofrequency ablation in the treatment of patients with primary liver cancer [J]. Journal of Practical Hepatology, 2023, 26(5): 706-709.
[14]	Zhang Shugeng, Zhang Shaobo, Zhu Zebin, et al. Early post-operational complications in patients with orthotopic liver transplantation receiving different deceased donors [J]. Journal of Practical Hepatology, 2023, 26(5): 738-741.
[15]	Ye Chaorong, Zhang Tao, Wu Yongjun, et al. Comparison of laparoscopic common bile duct exploration and ERCP in the treatment of patients with common bile duct stones [J]. Journal of Practical Hepatology, 2023, 26(5): 742-745.